UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 277

Sortiert nach

The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project

Haematologica (Roma), 2018-07, Vol.103 (7), p.1191

2018

Volltextzugriff (PDF)

Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma

Journal of clinical oncology, 2007-07, Vol.25 (21), p.3109-3115

2007

Volltextzugriff (PDF)

Mycosis Fungoides and Sezary Syndrome

Hematology/oncology clinics of North America, 2017-04, Vol.31 (2), p.297-315

2017

Volltextzugriff (PDF)

Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma

Haematologica (Roma), 2015-06, Vol.100 (6), p.794

2015

Volltextzugriff (PDF)

Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma

Experimental hematology & oncology, 2021-02, Vol.10 (1), p.15-11, Article 15

2021

Volltextzugriff (PDF)

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry

Acta haematologica, 2020-01, Vol.143 (1), p.40-50

2020

Volltextzugriff (PDF)

Immunologic mechanisms of antitumor activity

Seminars in oncology, 2002-06, Vol.29 (3), p.5-11

Foss, Francine M

2002

Volltextzugriff (PDF)

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Blood, 2018-02, Vol.131 (8), p.888-898

2018

Volltextzugriff (PDF)

Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides

Journal of the American Academy of Dermatology, 2013-10, Vol.69 (4), p.537-543

2013

Volltextzugriff (PDF)

Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease

Blood, 2002-08, Vol.100 (3), p.941-947

2002

Volltextzugriff (PDF)

Genomic landscape of cutaneous T cell lymphoma

Nature genetics, 2015-09, Vol.47 (9), p.1011-1019

2015

Volltextzugriff (PDF)

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma

Blood, 2015-03, Vol.125 (12), p.1883-1889

2015

Volltextzugriff (PDF)

Treatment strategies for peripheral T-cell lymphomas

Best practice & research. Clinical haematology, 2013-03, Vol.26 (1), p.43-56

Foss, Francine M., MD

2013

Volltextzugriff (PDF)

Necrotic papulonodules on the legs

JAAD Case Reports, 2021-05, Vol.11, p.10-12

2021

Volltextzugriff (PDF)

Peripheral T-cell lymphoma

Blood, 2011-06, Vol.117 (25), p.6756-6767

2011

Volltextzugriff (PDF)

Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma

Drugs (New York, N.Y.), 2010-02, Vol.70 (3), p.273-286

2010

Volltextzugriff (PDF)

B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma

JAAD Case Reports, 2021-02, Vol.8, p.89-92

2021

Volltextzugriff (PDF)

Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients

Blood, 2017-11, Vol.130 (19), p.2073-2083

2017

Volltextzugriff (PDF)

Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate

Leukemia & lymphoma, 2019-10, Vol.60 (12), p.2927-2930

2019

Volltextzugriff (PDF)

Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome

Clinical lymphoma, myeloma and leukemia, 2017-08, Vol.17 (8), p.520-526.e2

2017

Volltextzugriff (PDF)

Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas

American journal of hematology, 2020-02, Vol.95 (2), p.151-155

2020

Volltextzugriff (PDF)

Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study

American journal of hematology, 2018-11, Vol.93 (11), p.1318-1326

2018

Volltextzugriff (PDF)

BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition

Oncotarget, 2018-06, Vol.9 (49), p.29193-29207

2018

Volltextzugriff (PDF)

Peripheral T cell lymphoma, not otherwise specified (PTCL‐NOS). A new prognostic model developed by the International T cell Project Network

British journal of haematology, 2018-06, Vol.181 (6), p.760-769

2018

Volltextzugriff (PDF)

1 – 25 von 277

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(253)
Mit Volltextzugriff
(254)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(118)
Humans
(117)
Life Sciences & Biomedicine
(117)
Middle Aged
(66)
Hematology
(65)
Female
(60)
Oncology
(59)
Male
(57)
Aged
(56)
Adult
(53)
Biological And Medical Sciences
(41)
Medical Sciences
(41)
Aged, 80 And Over
(30)
Lymphoma
(26)
Treatment Outcome
(26)
Hematologic And Hematopoietic Diseases
(23)
Lymphoma, T-Cell, Cutaneous - Drug Therapy
(22)
Skin Neoplasms - Drug Therapy
(22)
Skin Neoplasms - Pathology
(21)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(18)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project

Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma

Mycosis Fungoides and Sezary Syndrome

Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma

Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry

Immunologic mechanisms of antitumor activity

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides

Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease

Genomic landscape of cutaneous T cell lymphoma

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma

Treatment strategies for peripheral T-cell lymphomas

Necrotic papulonodules on the legs

Peripheral T-cell lymphoma

Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma

B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma

The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study

Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients

Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate

Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome

Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas

Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study

BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition

Peripheral T cell lymphoma, not otherwise specified (PTCL‐NOS). A new prognostic model developed by the International T cell Project Network

Suchergebnisse filtern